|
Dr. Perry is an expert in medical and pharmaceutical product development and associated regulatory strategy and implementation. His previous background as the head of the Regulatory Affairs Department and then as the head of the Cell and Gene Therapy Businesses at Novartis, will be of immeasurable benefit to Xeno as the company moves to realize the full commercial potential of its unique intellectual property portfolio.
Biography
Dr. Perry is the Chief Development Officer of VIA Pharmaceuticals, a portfolio company of Bay City Capital Ventures. He was formerly Founder, CEO and Director of Extropy Pharmaceuticals, CEO and Director of Pharsight Corporation (PHST), CEO and Director of Novartis’ Cell and Gene Therapy Businesses (SyStemix, Inc., and Genetic Therapy, Inc.), Global Head of R&D for Baxter BioPharmaceuticals, Vice President for Worldwide Regulatory Affairs at Novartis Pharma and Vice President of Syntex Corporation. He is currently a Director of Targeted Genetics Corporation (TGEN) and a Venture Partner at Bay City Capital, LLC.
Dr. Perry holds a B.Sc. in Physics, D.V.M., and Ph.D. in Cardiopulmonary Pharmacology from the University of Guelph. He is a Fellow of the American College of Veterinary Pharmacology and Therapeutics, and completed The Executive Management Program at Harvard Business School. | 